Abilify Asimtufii - Beechwood Capital

Drug Profile

ModalitySmall molecule

RouteIM

Therapy AreaNeurology

Launch2023-04-27

Peak Sales Est$2000M

Formulations[{"id":"asimtufii-im","route":"IM","device":"Pre-filled syringe (720mg, 960mg)","setting":"HCP_ONLY"

Companies

LUN (CO_DEVELOPER)20%

4578 (ORIGINATOR)80%

Expert: Partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors with antagonism at 5-HT2A receptors. Stabilizes dopaminergic and serotonergic neurotransmission by acting as a functional agonist in hypodopaminergic states and antagonist in hyperdopaminergic states.

Everyday: Fine-tunes dopamine and serotonin signals in the brain — like a thermostat that adjusts these chemical messengers up or down depending on what the brain needs, rather than simply turning them on or off.

Targets: []

Indication	Stage	Key Study	Regional Status
Schizophrenia	APPROVED	NCT03346525	[{"stage":"APPROVED","region":"US","approval_date":"2023-04-27"}]
Bipolar I maintenance	APPROVED	NCT03346525	[{"stage":"APPROVED","region":"US","approval_date":"2023-04-27"}]

First-ever once-every-two-months LAI antipsychotic. Replacement for Abilify Maintena. Ready-to-use, no reconstitution.